GlassScriptPhysician profile
Emily A Poland
NPI 1164621447
$3,154.13
in general payments reported to CMS, 2019-2025
21 companies · $84.20 in 2025
The $84.20 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,121 · 2020: $217 · 2021: $550 · 2022: $481 · 2023: $304 · 2024: $396 · 2025: $84.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,418.23 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $827.98 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $151.37 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.04 | 2019-2022 | |
| Shionogi INC | $112.67 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $99.22 | 2019 | |
| Pfizer INC. | $58.27 | 2023-2024 | |
| Daiichi Sankyo INC. | $53.69 | 2019 | |
| Merck Sharp & Dohme LLC | $52.64 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $48.58 | 2021-2022 | |
| Gilead Sciences, INC. | $36.17 | 2020-2023 | |
| Intercept Pharmaceuticals, INC. | $28.53 | 2019-2020 | |
| Ucb, INC. | $22.65 | 2019 | |
| Celgene Corporation | $22.49 | 2023 | Zeposia |
| Qol Medical, LLC | $18.80 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $18.04 | 2019 | |
| Redhill Biopharma INC. | $17.03 | 2021 | |
| Allergan, INC. | $15.66 | 2019 | |
| Vivus LLC | $15.00 | 2021 | |
| Braintree Laboratories, INC. | $12.01 | 2020 | |
| Alfasigma USA, INC. | $11.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Poland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.